SCHEMBL4775622

SCHEMBL4775622

COCCC(=O)N1CCc2c(sc(NC(=O)C3CC3c3cccc(OC)c3)c2C#N)C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
MAPT P10636 4/20 0.58
KDM4E B2RXH2 2/20 0.51
GRM1 Q13255 1/20 0.49
MAPK10 P53779 2/20 0.46
STAT3 P40763 2/20 0.46
MAPK9 P45984 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GRM5 P41594 3/20 0.46
DGAT2 Q96PD7 2/20 0.44
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777490 0.95 MEN1 (0.57) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4766102 0.93 MEN1 (0.58) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4767801 0.92 MEN1 (0.59) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4048307 0.89 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4775702 0.89 MEN1 (0.52) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4773271 0.88 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL2896268 0.87 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4773187 0.87 MEN1 (0.54) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4775963 0.87 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL4767886 0.87 MEN1 (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893618-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-05 EP claimed
WO-2006125815-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO claimed
US-7763728-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-07-27 US disclosed
US-7763728-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-07-27 US disclosed
US-20090257977-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES PEKARI KLAUS 2009-10-15 US disclosed
US-20080260749-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-10-23 US disclosed
US-20080260749-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257977-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES BAX, BCL2, CCAR2 ALDH1A1 632/4885MEN1 4735/4885KMT2A 2418/4885
US-20080260749-A1 Novel Tetrahydropyridothiophenes BAX, BCL2, CCAR2 ALDH1A1 615/4885MEN1 4691/4885KMT2A 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.